glofitamab induces durable complete remissions in patients with relapsed large b-cell lymphoma
Published 2 years ago • 677 plays • Length 4:46Download video MP4
Download video MP3
Similar videos
-
2:40
phase ii study of glofitamab in patients with r/r lbcl
-
6:47
michael dickinson, mbbs, dmedsc, on a phase ii trial of glofitamab in dlbcl
-
7:48
glofitamab, a cd20/cd3 bispecific antibody, in the treatment of r/r dlbcl
-
2:43
insights into phase i/ii study assessing fixed-duration glofitamab treatment for r/r lbcl
-
5:46
glofitamab and polatuzumab vedotin in dlbcl
-
2:33
glofitamab as a single agent in heavily pretreated patients with dlbcl
-
2:08
the current and future role of bispecifics in r/r dlbcl: epcoritamab, glofitamab & more
-
2:18
update on phase i/ii study of glofitamab monotherapy in r/r mcl
-
3:58
extended follow-up of glofitamab monotherapy in r/r lbcl: durability of cr and likelihood of crs
-
5:12
the emerging potential of bispecific antibodies as monotherapy & in combination for b-cell lymphoma
-
3:26
what is the rationale behind the combination of glofitamab polatuzumab in patients with r/r dlbcl?
-
3:02
efficacy of epcoritamab and glofitamab in diffuse large b-cell lymphoma
-
3:48
coalition: glofitamab r-chop or glofitamab pola-r-chp in high-risk dlbcl
-
46:48
relapsed and refractory diffuse large b-cell lymphoma
-
1:46
phase i study of costimulatory bispecific antibody ro7227166 combined with glofitamab in r/r b-nhl
-
1:12:05
relapsed / refractory diffuse large b-cell lymphoma (dlbcl) with dr gareth gregory
-
5:30
glofitamab in r/r dlbcl: updated safety and efficacy data
-
5:44
glofitamab and obinutuzumab in r/r mcl
-
3:10
axicabtagene ciloleucel in patients with refractory large b cell lymphoma